HD-OPM Archive
Topics › GLP-1 drugs (semaglutide, tirzepatide)

Evidence is building that GLP-1 drugs may slow aging in mammals

Louis Nervegna · Nov 10, 2026 · ♥ 7 reactions · 7 comments · original Facebook post
GLP-1 drugs (semaglutide, tirzepatide)Aging & longevity
AI summary & key facts

Louis comments that evidence is accumulating that GLP-1 agonists slow aging in mammals, in line with calorie restriction extending lifespan in animals. The shared investigation covers the semaglutide 3.1-year biological age claim and a 2026 Nature study of longer-lived old female mice.

The evidence is slowly building that GLP1 agonist drugs slow the aging process in mammals.

This should not be surprising, given how decades of previous research has proven that calorie restriction robustly extends lifespan in many different animal species.

#glp1HD #glp1agingHD #calorierestrictionHD #agingHD #longevityHD

Research cited

GLP-1 drugs like Ozempic are usually discussed as weight-loss medicines. But in October 2025, a testing company announced that semaglutide had reversed biological age by 3.1 years, and in 2026 a study in Nature reported that old female mice given the drug lived longer. The story of these drugs began with a gut hormone the body destroys in about two minutes, a lizard venom, and heart safety trials that were never meant to find a benefit. This investigation follows that evidence from the original discovery to the latest human trials to determine what GLP-1 drugs actually do, and whether their reputation as longevity drugs has been earned.

← newer: Olive oil has the strongest trial evidence, but canola and solder: FDA warns GLP-1 drugs can rarely reduce optic nerve blood fl →